168 related articles for article (PubMed ID: 23678595)
1. [Paliperidone, risperidone].
Takeuchi K; Sanjo K; Sakai A
Nihon Rinsho; 2013 Apr; 71(4):654-9. PubMed ID: 23678595
[TBL] [Abstract][Full Text] [Related]
2. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
Kim SW; Chung YC; Lee YH; Lee JH; Kim SY; Bae KY; Kim JM; Shin IS; Yoon JS
Int Clin Psychopharmacol; 2012 Sep; 27(5):267-74. PubMed ID: 22809972
[TBL] [Abstract][Full Text] [Related]
3. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
Fowler JA; Bettinger TL; Argo TR
Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
[TBL] [Abstract][Full Text] [Related]
4. Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent.
Prescrire Int; 2007 Dec; 16(92):236-7. PubMed ID: 18092400
[TBL] [Abstract][Full Text] [Related]
5. Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia.
Yang DS; Seong SJ; Yoon YR; Lim MS; Kwak KH; Lee SJ
J Psychopharmacol; 2014 Apr; 28(4):341-8. PubMed ID: 24346811
[TBL] [Abstract][Full Text] [Related]
6. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.
Berwaerts J; Cleton A; Rossenu S; Talluri K; Remmerie B; Janssens L; Boom S; Kramer M; Eerdekens M
J Psychopharmacol; 2010 Jul; 24(7):1011-8. PubMed ID: 19825908
[TBL] [Abstract][Full Text] [Related]
7. Paliperidone: An improvement over risperidone?
Dopheide JA
Am J Health Syst Pharm; 2008 Mar; 65(5):401. PubMed ID: 18281730
[No Abstract] [Full Text] [Related]
8. What are the nursing implications when using paliperidone prolonged release for people with schizophrenia.
Jones A
J Psychiatr Ment Health Nurs; 2008 Dec; 15(10):792-9. PubMed ID: 19012670
[TBL] [Abstract][Full Text] [Related]
9. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.
Pani L; Marchese G
Expert Opin Drug Deliv; 2009 Mar; 6(3):319-31. PubMed ID: 19317589
[TBL] [Abstract][Full Text] [Related]
10. Paliperidone extended-release: does it have a place in antipsychotic therapy?
Gahr M; Kölle MA; Schönfeldt-Lecuona C; Lepping P; Freudenmann RW
Drug Des Devel Ther; 2011 Mar; 5():125-46. PubMed ID: 21448450
[TBL] [Abstract][Full Text] [Related]
11. Paliperidone extended-release for the treatment of schizophrenia.
Marino J; Caballero J
Pharmacotherapy; 2008 Oct; 28(10):1283-98. PubMed ID: 18823223
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of risperidone on positive features of schizophrenia.
McEvoy JP
J Clin Psychiatry; 1994 May; 55 Suppl():18-21. PubMed ID: 7520904
[TBL] [Abstract][Full Text] [Related]
13. The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial.
Suzuki H; Gen K; Inoue Y; Hibino H; Mikami A; Matsumoto H; Mikami K
Int J Psychiatry Clin Pract; 2014 Jan; 18(1):58-62. PubMed ID: 24047427
[TBL] [Abstract][Full Text] [Related]
14. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.
Turkoz I; Bossie CA; Lindenmayer JP; Schooler N; Canuso CM
BMC Psychiatry; 2011 Feb; 11():21. PubMed ID: 21299844
[TBL] [Abstract][Full Text] [Related]
15. Paliperidone for schizophrenia.
Dolder C; Nelson M; Deyo Z
Am J Health Syst Pharm; 2008 Mar; 65(5):403-13. PubMed ID: 18281731
[TBL] [Abstract][Full Text] [Related]
16. Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability.
Citrome L
Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):873-88. PubMed ID: 22632481
[TBL] [Abstract][Full Text] [Related]
17. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.
Canuso CM; Youssef EA; Bossie CA; Turkoz I; Schreiner A; Simpson GM
Int Clin Psychopharmacol; 2008 Jul; 23(4):209-15. PubMed ID: 18545059
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Li H; Rui Q; Ning X; Xu H; Gu N
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
[TBL] [Abstract][Full Text] [Related]
19. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.
Kim SW; Yoon JS; Kim YS; Ahn YM; Kim CE; Go HJ; Chee IS; Jung SW; Chung YC; Kim YD; Joe S; Lee J; Kwon YJ; Yoon BH; Jae YM
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):228-35. PubMed ID: 22516251
[TBL] [Abstract][Full Text] [Related]
20. Study of the efficacy and safety of switching from risperidone to paliperidone in elderly patients with schizophrenia.
Suzuki H; Gen K; Otomo M; Inoue Y; Hibino H; Mikami A; Matsumoto H; Mikami K
Psychiatry Clin Neurosci; 2013 Feb; 67(2):76-82. PubMed ID: 23438159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]